ProMIS Neurosciences (PMN) Total Liabilities (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Total Liabilities came in at $6.7 million in Q1 2026, up 60.34% YoY from $4.2 million in Q1 2025, and down 35.89% on a QoQ basis from $10.4 million in Q4 2025.
ProMIS Neurosciences (PMN) Total Liabilities (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Total Liabilities data on file, last reported at $6.7 million in Q1 2026.
- Quarterly Total Liabilities rose 60.34% year-over-year to $6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (up 60.34% YoY) and the FY2025 annual result came in at $10.4 million, up 330.86% from the prior year.
- Total Liabilities eased to $6.7 million in Q1 2026, from $10.4 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $17.2 million in Q3 2024 to a low of $2.4 million in Q4 2024.
- A 5-year average of $8.0 million and a median of $9.1 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities plunged 75.44% — and 2025, when it soared 330.86%.
- Tracing PMN's Total Liabilities over 5 years: stood at $8.3 million in 2022, then advanced by 19.26% to $9.9 million in 2023, then sank by 75.44% to $2.4 million in 2024, then soared by 330.86% to $10.4 million in 2025, then sank by 35.89% to $6.7 million in 2026.
- The last three Total Liabilities figures came in at $6.7 million (Q1 2026), $10.4 million (Q4 2025), and $12.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - | 7.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.29 Mn |
| Mar 31, 2026 | 6.69 Mn |
| Dec 31, 2025 | 10.44 Mn |
| Sep 30, 2025 | 12.27 Mn |
| Jun 30, 2025 | 9.89 Mn |
| Mar 31, 2025 | 4.17 Mn |
| Dec 31, 2024 | 2.42 Mn |
| Sep 30, 2024 | 17.24 Mn |
| Jun 30, 2024 | 3.69 Mn |
| Mar 31, 2024 | 3.47 Mn |
| Dec 31, 2023 | 9.87 Mn |
| Sep 30, 2023 | 11.12 Mn |
| Jun 30, 2023 | 10.03 Mn |
| Mar 31, 2023 | 10.61 Mn |
| Dec 31, 2022 | 8.27 Mn |
| Sep 30, 2022 | 4.65 Mn |
| Jun 30, 2022 | 3.48 Mn |
| Dec 31, 2021 | 12.09 Mn |